New cell combo targets tough stomach cancer
Disease control
Recruiting now
This early-stage trial tests a new treatment for advanced stomach cancer that has not responded to standard therapies. It combines a vaccine made from the patient's own tumor markers (neoantigens) with immune cells trained to attack the cancer. The main goals are to see if the co…
Phase: PHASE1 • Sponsor: Jia Wei • Aim: Disease control
Last updated May 04, 2026 16:31 UTC